ArticleFrontiers in public health2022

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.

Yamin Shu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.